Free tool
FAERS Monitor: Eryc
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 050536 or its brand name (Eryc, Erythromycin). Reports on generic versions are filed under their own applications.
Reports
18,337
Serious
11,285
62% of reports
Hospitalization
4,843
Death reported
1,661
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug hypersensitivity4,099
- nausea1,272
- vomiting1,107
- drug ineffective1,100
- diarrhoea1,076
- fatigue1,058
- dyspnoea1,050
- rash1,018
- off label use953
- headache883
- dizziness791
- pain787
- pyrexia712
- malaise706
- hypersensitivity684
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 202 |
| 2005 | 231 |
| 2006 | 225 |
| 2007 | 209 |
| 2008 | 290 |
| 2009 | 424 |
| 2010 | 485 |
| 2011 | 443 |
| 2012 | 625 |
| 2013 | 574 |
| 2014 | 579 |
| 2015 | 664 |
| 2016 | 1,201 |
| 2017 | 1,085 |
| 2018 | 1,379 |
| 2019 | 1,759 |
| 2020 | 1,294 |
| 2021 | 1,299 |
| 2022 | 1,109 |
| 2023 | 1,260 |
| 2024 | 1,272 |
| 2025 | 1,079 |
| 2026 | 648 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,035,822 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| drug hypersensitivitySignal | 4,099 | 24.8 | 24.1 | 92,464 |
| hypersensitivitySignal | 684 | 4.2 | 3.9 | 1,698 |
| vomitingSignal | 1,107 | 2.7 | 2.6 | 1,212 |
| rashSignal | 1,018 | 2.7 | 2.5 | 1,093 |
| pyrexiaSignal | 712 | 2.4 | 2.2 | 567 |
| dyspnoeaSignal | 1,050 | 2.1 | 2.0 | 644 |
| diarrhoea | 1,076 | 1.9 | 1.8 | 482 |
| malaise | 706 | 1.8 | 1.7 | 279 |
| nausea | 1,272 | 1.8 | 1.7 | 510 |
| dizziness | 791 | 1.8 | 1.7 | 298 |
| headache | 883 | 1.6 | 1.5 | 213 |
| fatigue | 1,058 | 1.6 | 1.5 | 220 |
| pain | 787 | 1.5 | 1.4 | 121 |
| off label use | 953 | 1.2 | 1.2 | 49 |
| drug ineffective | 1,100 | 1.0 | 0.9 | 2 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.